Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NADOLOL | 80MG | TABLET | Resolved | 2023-12-08 | 2024-01-26 | 212919 |
| APO-NADOLOL | 40MG | TABLET | Resolved | 2022-09-30 | 2022-11-20 | 170801 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2021-05-28 | 2021-07-09 | 140075 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2021-08-13 | 2021-08-31 | 144142 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2019-08-07 | 2019-08-19 | 91091 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2017-10-11 | 2017-10-25 | 25299 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2017-11-28 | 2018-01-16 | 31016 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2018-08-21 | 2018-09-28 | 58594 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2018-11-21 | 2019-02-01 | 67404 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2020-04-06 | 2020-05-04 | 111060 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2021-02-12 | 2021-03-15 | 133991 |
| APO-NALTREXONE | 50MG | TABLET | Resolved | 2023-01-06 | 2023-03-30 | 180119 |
| APO-NAPRO-NA | 275MG | TABLET | Resolved | 2018-05-15 | 2018-10-05 | 49499 |
| APO-NAPRO-NA | 275MG | TABLET | Resolved | 2022-06-06 | 2022-08-22 | 162077 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164744 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2023-05-26 | 2023-07-27 | 193215 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2019-01-03 | 2019-02-08 | 71139 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2017-05-24 | 2018-10-05 | 11082 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-02-23 | 2023-05-06 | 185459 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-03-02 | 2023-05-06 | 185942 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |